Troglitazone (Rezulin)

A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.

Also Known As:

Rezulin; Prelay; 5-(4-((6-Hydroxy-2,5,7,8-tetramethylchroman-2-yl-methoxy)benzyl)-2,4-thiazolidinedione) - T; CS 045; CS-045; CS045; 2,4-Thiazolidinedione, 5-((4-((3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy)phenyl)methyl)-

Networked: 901 relevant articles (116 outcomes, 189 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Buchanan, Thomas A: 10 articles (07/2008 - 08/2002)
2.	Welbourne, Tomas: 8 articles (02/2011 - 01/2002)
3.	Boisbrun, Michel: 7 articles (02/2020 - 12/2008)
4.	Flament, Stéphane: 7 articles (02/2020 - 12/2008)
5.	Hodis, Howard N: 7 articles (07/2008 - 08/2002)
6.	Xiang, Anny H: 7 articles (07/2008 - 09/2002)
7.	Grillier-Vuissoz, Isabelle: 6 articles (10/2017 - 12/2008)
8.	Chen, Ching-Shih: 6 articles (04/2009 - 04/2005)
9.	Motomura, Wataru: 6 articles (03/2009 - 07/2002)
10.	Okumura, Toshikatsu: 6 articles (03/2009 - 07/2002)

Related Diseases

1.	Insulin Resistance 01/01/2002 - "Troglitazone, regardless of dose, significantly improved insulin sensitivity assessed by the homeostasis model (HOMA). " 06/01/2000 - "Troglitazone administration significantly improved insulin resistance, but did not affect pancreatic beta-cell function as evaluated by the homeostasis model assessment (HOMA). " 05/01/2000 - "AIRt (P = 0.001) and 30-min dINS (P = 0.02) fell with improved insulin sensitivity during troglitazone treatment, so that the disposition index for each of these measures of beta-cell function did not change significantly from baseline (P > 0.20) or compared with placebo (P > 0.3). " 04/01/2005 - "This effect of troglitazone was in part due to improved insulin sensitivity with maintenance of insulin secretion. " 02/01/2003 - "Because troglitazone (Tgz) improves both hormonal profiles and insulin sensitivity, we tested whether Tgz treatment ameliorates endothelial function in these patients. "
2.	Type 2 Diabetes Mellitus (MODY) 09/01/2001 - "Troglitazone is effective in approximately 50% in patients with type 2 diabetes (NIDDM). " 02/01/2003 - "We concluded that troglitazone treatment for 12 weeks improved endothelial function in the macrocirculation of patients with recently diagnosed type 2 diabetes and no clinical evidence of macrovascular disease. " 08/01/2000 - "Efficacy of troglitazone on body fat distribution in type 2 diabetes." 05/01/2003 - "A study to survey susceptible genetic factors responsible for troglitazone-associated hepatotoxicity in Japanese patients with type 2 diabetes mellitus." 07/01/1999 - "The present study examined the hemodynamic mechanisms of blood pressure (BP) lowering by troglitazone in patients with type 2 diabetes mellitus (DM) at rest and during a mental arithmetic test (MAT). "
3.	Hyperinsulinism (Hyperinsulinemia) 03/01/1995 - "The present study was performed to evaluate whether the amelioration of hyperinsulinemia by troglitazone lowers blood pressure in essential hypertensives. " 09/01/1997 - "The effects of troglitazone, administered as a food admixture (24 mg/day) for 6 months, on hyperinsulinemia and BP were examined in WHHL rabbits. " 07/01/2001 - "In WHHL rabbits, troglitazone dose-dependently reduced hyperinsulinemia, improved beta-cell function, and increased insulin sensitivity." 05/01/2002 - "These results suggest that the beneficial effects of troglitazone in PCOS may not be due solely to improvement of peripheral insulin resistance and hyperinsulinemia, but also to a possible direct effect on ovarian steroidogenesis." 02/01/2000 - "Beneficial effects of troglitazone on multiple risk factor syndrome have been reported in terms of blood pressure lowering effect and ameliorations of dyslipidemia and hyperinsulinemia. "
4.	Hyperglycemia 01/01/1998 - "This decrease of SBF was significantly improved (2.9+/-0.2 ml/min/100 g) by troglitazone treatment (approximately 220 mg/kg/day) for 7 days in STZ diabetic rats without alleviating hyperglycemia. " 03/01/1998 - "Troglitazone treatment largely prevented the hyperglycemia-induced decline in submaximal (116 +/- 7 micromol x kg(-1) x min[-1]) and maximal GDR (209 +/- 9 micromol x kg(-1) x min(-1); P < 0.05). " 11/01/1996 - "These findings clearly demonstrate that the hyperglycemia in STZ-induced diabetic rats receiving an insufficient number of islet grafts to reverse diabetes was ameliorated by troglitazone treatment." 04/01/1995 - "Since increased hepatic gluconeogenesis is a major cause of hyperglycemia in these diabetic animals, we evaluated the effect of long-term Troglitazone treatment on hepatic gluconeogenesis. " 09/01/1996 - "Troglitazone treatment did not attenuate the insulinopenia and hyperglycemia of diabetic rats, but it partially improved the hypertriglyceridemia. "
5.	Glucose Intolerance 07/01/1997 - "We conclude that administration of troglitazone to women with PCOS and impaired glucose tolerance ameliorates the metabolic and hormonal derangements characteristic of the syndrome. " 08/01/1997 - "Is troglitazone a real indication for obese subjects with impaired glucose tolerance?" 03/01/1998 - "Studies and abstracts chosen summarize the clinical action of troglitazone in healthy volunteers, in subjects with impaired glucose tolerance, and in patients with diabetes mellitus. " 03/01/2006 - "Troglitazone, a TZD that has since been removed from the market because of hepatoxicity, has been demonstrated to decrease the progression from normal or impaired glucose tolerance to overt Type 2 diabetes mellitus. " 03/01/1998 - "Data suggest that troglitazone decreases impaired glucose tolerance in nondiabetic obese subjects and leads to a reduction in both systolic and diastolic blood pressure in hypertensive type 2 diabetes mellitus patients. "

Related Drugs and Biologics

1.	Insulin (Novolin)
2.	Glucose (Dextrose)
3.	Metformin (Glucophage)
4.	PPAR gamma
5.	2,4-thiazolidinedione (thiazolidinedione)
6.	Ligands
7.	Pioglitazone (Actos)
8.	Hypoglycemic Agents (Hypoglycemics)
9.	Thiazolidinediones
10.	Rosiglitazone (Avandia)

Related Therapies and Procedures

1.	Therapeutics
2.	Glycemic Control
3.	Aftercare (After-Treatment)
4.	Photorefractive Keratectomy
5.	Injections